WINT (Windtree Therapeutics) רווח נקי למניה ב-12 החודשים האחרונים
Windtree Therapeutics (WINT) is pursuing the expansion of istaroxime, although development is complicated by a liquidity shortage and the regular issuance of new shares. On GURU.Markets, the trailing 12-month EPS reflects a recovery trend, where the value of 63.07 represents the most recent figure. High competition in the cardiology sector creates risks of more effective alternatives emerging, which could limit the company's market success.
%20%D7%A8%D7%95%D7%95%D7%97%20%D7%9C%D7%9E%D7%A0%D7%99%D7%94%20%D7%91%D7%90%D7%A8%D7%91%D7%A2%D7%AA%20%D7%94%D7%A8%D7%91%D7%A2%D7%95%D7%A0%D7%99%D7%9D%20%D7%94%D7%90%D7%97%D7%A8%D7%95%D7%A0%D7%99%D7%9D&width=1200&height=400&colorIndex=0&v=mwbxec28.yq-7cu2wow&start=20220704&end=20261111&filename=GURU_Markets_-_WINT_-_Windtree-Therapeutics_-_Earnings-per-share-for-the-last-four-quarters "Windtree Therapeutics - רווח למניה בשנים עשר החודשים האחרונים WINT (תקופה 04.07.2022 - 06.09.2025) | 👁️GURU.Markets👁️")
פילוחים אנליטיים ודוחות נתונים של חברת Windtree Therapeutics Inc. (WINT)
Developing peptide drugs for the therapy of cardiogenic shock requires colossal investments in the patent perimeter for Windtree Therapeutics (WINT). The EPS TTM metric is calculated by dividing the total annual net income by the total number of shares. This calculation offsets the effect of capital dilution during new issuances, revealing the actual efficiency of the business. The investor assesses the fundamental value of the asset, separating the financial result from marketing. This process is reflected in the net income per share over the last four quarters.
